U.S. FDA panel votes against Amylyx’s ALS drug over trial data concerns
Written by Black Hot Fire Network on March 30, 2022
March 30 (Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday voted against approving Amylyx Pharmaceuticals Inc's (AMLX.O) drug for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
The FDA advisory committee voted 6 to 4 against the treatment, saying . . .
